Compare Eli Lilly And Co (LLY) vs Zscaler Inc (ZS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Zscaler Inc — how do they compare? Eli Lilly And Co trades at $1,177.57 (market cap $1.04T), while Zscaler Inc trades at $234 (market cap $35.35B). The key difference: Eli Lilly And Co is far larger — about 29.4× Zscaler Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while Zscaler Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Zscaler Inc for 41 Days on average.
| LLY | ZS | |
|---|---|---|
Market Cap | $1.04T | $35.35B |
Volume | 3,064,878 | 3,726,203 |
Sector | Health | Technology |
52-Week High | $1.28K | $336.27 |
52-Week Low | $799.57 | $118.05 |
Typical Hold Time | 93 Days | 41 Days |
Enterprise Value | $1.09T | $33.73B |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
Zscaler (ZS) trades at $233.73, up 9.45% today, with a bullish technical outlook supported by moving averages and strong quarterly earnings beats. Revenue growth is robust, rising from $1.1B in 2022 to $2.67B in 2025, though the company remains unprofitable with a net margin of -1.88%. Recent news includes a CRO transition and an upcoming Investor Day, while analyst sentiment is overwhelmingly positive with 79.6% buy ratings.
The stock offers growth potential driven by cybersecurity demand and AI product adoption, but risks include persistent losses, high valuation multiples, and competitive pressures. The consensus price target of $222.83 suggests modest downside from current levels, requiring careful risk assessment amid volatile market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Zscaler Inc
Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →
